Vivos Therapeutics, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Seastar Medical Holding Corp.

Sharps Technology, Inc.

NeuroMetrix, Inc.

Vivos Therapeutics, Inc.

Ekso Bionics Holdings, Inc.

BioRestorative Therapies, Inc.

Creative Medical Technology Holdings, Inc.

ENDRA Life Sciences, Inc.

Aethlon Medical, Inc.

Navidea Biopharmaceuticals, Inc.

Nemaura Medical, Inc.

Why is Vivos Therapeutics, Inc. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -18.42% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -16.84

The company has declared Negative results for the last 5 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at USD -17.47 MM
ROCE(HY) Lowest at -1,528.85%
PRE-TAX PROFIT(Q) Lowest at USD -7.75 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -85.14%, its profits have fallen by -35.8%

Below par performance in long term as well as near term

Along with generating -85.14% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vivos Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Vivos Therapeutics, Inc.

-85.14%

-0.82

99.56%

S&P 500

20.78%

1.56

13.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.14%

EBIT Growth (5y)

-18.42%

EBIT to Interest (avg)

-16.84

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.43

Sales to Capital Employed (avg)

5.81

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

22.23%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.75

EV to EBIT

-1.13

EV to EBITDA

-1.21

EV to Capital Employed

2.06

EV to Sales

1.07

PEG Ratio

Dividend Yield

ROCE (Latest)

-182.34%

ROE (Latest)

-675.51%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

NET PROFIT(HY)

Higher at USD -14.58 MM

RAW MATERIAL COST(Y)

Fallen by -15.08% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -892.62 %

NET SALES(Q)

At USD 5.14 MM has Grown at 17.89%

-25What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -17.47 MM

ROCE(HY)

Lowest at -1,528.85%

PRE-TAX PROFIT(Q)

Lowest at USD -7.75 MM

NET PROFIT(Q)

Lowest at USD -7.68 MM

CASH AND EQV(HY)

Lowest at USD 4.14 MM

OPERATING PROFIT(Q)

Lowest at USD -6.16 MM

Here's what is working for Vivos Therapeutics, Inc.

Net Sales

At USD 5.14 MM has Grown at 17.89%

over average net sales of the previous four periods of USD 4.36 MM

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Debt-Equity Ratio

Lowest at -892.62 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -15.08% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Vivos Therapeutics, Inc.

Pre-Tax Profit

At USD -7.75 MM has Fallen at -46.03%

over average net sales of the previous four periods of USD -5.31 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -7.68 MM has Fallen at -45.14%

over average net sales of the previous four periods of USD -5.29 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -17.47 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Pre-Tax Profit

Lowest at USD -7.75 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -7.68 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit

Lowest at USD -6.16 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Cash and Eqv

Lowest at USD 4.14 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents